The accuracy and speed of analytical measurements play a critical role in biopharmaceutical development and manufacturing. In particular, the ability to quantify both active pharmaceutical ingredients (APIs) and formulation excipients – such as buffers, amino acids, sugars, and surfactants – is essential for ensuring product quality, process consistency, and regulatory compliance.
The pharmaceutical and biotech industries are not only one of the most prominent users of cold storage solutions today but are also one of the market’s most important growth drivers. Several factors, including the rise of temperature sensitive drugs, growing energy prices, and increasing regulatory scrutiny are inevitably compelling the pharmaceutical industry to consider its use of the global cold chain with sustainability in mind.
Are your perceptions of the CMO marketplace serving your drug program—or holding it back? If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028. In such a competitive market, how should a project sponsor navigate the choice between one CMO and another? To find the answer, many sponsors begin by distinguishing between typical stand-alone CMOs and an embedded CMO that operates under a parent company—AbbVie, in the case of AbbVie Contract Manufacturing (AbbVie).
Antibody-based therapeutics have reshaped modern medicine. With demand soaring, choosing the appropriate production path can save months and millions.
According to Grand View Research, the global therapeutic antibody market will surpass US $2.21 billion by 2030.
Based on our expertise in monoclonal antibody production, let’s take a look at how each antibody type is produced, contrasts their timelines, costs, and use-cases, and ends with clear next steps to keep your project moving.
As sustainability expectations continue to rise across the pharmaceutical industry, drug makers, CDMOs, and equipment suppliers are under increasing pressure to reduce waste, energy use, and environmental impact. Find out in this exclusive Drug Development & Delivery eBook how companies like Bespak have taken steps to support the scale of commercial-scale manufacturing of a low-carbon Pressurized Metered Dose Inhaler. Additionally, learn how Aptar Pharma Injectables division has undertaken an effort to identify the principal sources of emissions across its elastomeric closure solutions. Finally, a new sustainability report reveals what the pharma industry is doing particularly well – and not so well – in its sustainability endeavors.
Outsourcing formulation development and manufacturing can help drug developers address complex dosage forms, scale-up risks, regulatory demands, and accelerated timelines by connecting projects with CDMO partners that offer specialized expertise, integrated workflows, and scalable manufacturing support.
Dissolution-permeation testing is helping drug developers better predict how food affects oral drug absorption by measuring both drug solubilization and membrane permeation, reducing the risk of misleading results from dissolution data alone.
PCI Pharma Services provides world-class solutions through intelligence, ingenuity and innovation, together, delivering life-changing therapies. With integration from inception and quality at our core, PCI’s development, manufacturing, clinical trial services, advanced drug delivery and packaging capabilities combine to minimize time-to-market and maximize opportunities for commercial success. PCI serves as an extension of its customers’ value chains, toward the shared goal of improving patients’ lives.
In a 2025 industry survey (1), 76% of respondents selected ‘risk of thermal degradation’ as a source of hesitation to pursue hot melt extrusion (HME). Concerns about heat-sensitive APIs frequently lead development teams to rule out HME early — …
The cell and gene therapy (CGT) product market is expected to grow at a very high rate of around 20-30% per year over the next 10 years. Increasing number of approvals, expansion of target diseases, accelerated investment and innovation, and …
Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.
In a recent panel discussion, GlobalData’s Director …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
September 9 – Bioavailability
September 16 – Capsules
September 23 – Analytical Testing
September 30 – Formulation Development